Pediatrix Medical Group, Inc. (NYSE:MD) Shares Purchased by Nordea Investment Management AB

Nordea Investment Management AB raised its position in shares of Pediatrix Medical Group, Inc. (NYSE:MD) by 51.6% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 263,633 shares of the company’s stock after purchasing an additional 89,739 shares during the quarter. Nordea Investment Management AB owned 0.31% of Pediatrix Medical Group worth $3,504,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of MD. Rubric Capital Management LP boosted its holdings in Pediatrix Medical Group by 797.0% in the second quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company’s stock valued at $61,532,000 after purchasing an additional 7,241,400 shares during the last quarter. Dana Investment Advisors Inc. lifted its holdings in shares of Pediatrix Medical Group by 80.3% in the 2nd quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company’s stock valued at $7,725,000 after buying an additional 455,785 shares during the period. Weiss Asset Management LP boosted its stake in shares of Pediatrix Medical Group by 50.5% in the third quarter. Weiss Asset Management LP now owns 912,818 shares of the company’s stock worth $10,580,000 after buying an additional 306,143 shares during the last quarter. Cubist Systematic Strategies LLC grew its holdings in Pediatrix Medical Group by 639.4% during the second quarter. Cubist Systematic Strategies LLC now owns 290,336 shares of the company’s stock worth $2,192,000 after acquiring an additional 251,072 shares during the period. Finally, RBF Capital LLC purchased a new position in Pediatrix Medical Group during the third quarter valued at approximately $1,695,000. 97.71% of the stock is owned by institutional investors and hedge funds.

Pediatrix Medical Group Price Performance

MD opened at $12.46 on Friday. The stock’s 50-day moving average price is $14.35 and its 200 day moving average price is $11.54. Pediatrix Medical Group, Inc. has a 12-month low of $6.62 and a 12-month high of $16.41. The firm has a market cap of $1.07 billion, a price-to-earnings ratio of -4.07, a PEG ratio of 2.00 and a beta of 1.58. The company has a current ratio of 1.42, a quick ratio of 1.42 and a debt-to-equity ratio of 0.83.

Pediatrix Medical Group (NYSE:MD) last announced its quarterly earnings data on Friday, November 1st. The company reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.07. The firm had revenue of $511.20 million during the quarter, compared to analysts’ expectations of $498.87 million. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The business’s quarterly revenue was up .9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.29 earnings per share. As a group, sell-side analysts expect that Pediatrix Medical Group, Inc. will post 1.26 earnings per share for the current year.

Insiders Place Their Bets

In other Pediatrix Medical Group news, EVP Mary Ann E. Moore sold 8,108 shares of the stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $16.00, for a total value of $129,728.00. Following the transaction, the executive vice president now directly owns 135,810 shares in the company, valued at $2,172,960. This represents a 5.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Mark S. Ordan sold 27,600 shares of the business’s stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $15.35, for a total transaction of $423,660.00. Following the sale, the director now owns 138,683 shares of the company’s stock, valued at $2,128,784.05. This represents a 16.60 % decrease in their position. The disclosure for this sale can be found here. 2.00% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. Macquarie started coverage on shares of Pediatrix Medical Group in a research note on Monday, December 16th. They set an “outperform” rating and a $18.00 price objective on the stock. Truist Financial cut their price objective on shares of Pediatrix Medical Group from $16.00 to $15.00 and set a “hold” rating for the company in a report on Monday, January 6th. UBS Group increased their target price on shares of Pediatrix Medical Group from $10.50 to $16.50 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Jefferies Financial Group lifted their price target on Pediatrix Medical Group from $14.00 to $18.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Finally, Mizuho increased their price target on Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 19th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $16.25.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.